Ever Supreme Bio Technology Co (ROCO:6712) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Ever Supreme Bio Technology Co had a gross margin of 72.37% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Ever Supreme Bio Technology Co Gross Margin % Related Terms
Ever Supreme Bio Technology Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ever Supreme Bio Technology Co Gross Margin % Chart
ROCO:6712 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Ever Supreme Bio Technology Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ever Supreme Bio Technology Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ever Supreme Bio Technology Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Ever Supreme Bio Technology Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Ever Supreme Bio Technology Co (ROCO:6712) has a Gross Margin % of 72.37% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Ever Supreme Bio Technology Co and its competitors. This is 13% above median its historical median of 63.92. According to the industry distribution chart, Ever Supreme Bio Technology Co ranks #286 out of 730 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Ever Supreme Bio Technology Co's Gross Margin % too high?
Ever Supreme Bio Technology Co's current Gross Margin % of 72.37% is 13% above median its 10-year median of 63.92. The Biotechnology industry median Gross Margin % is 60.91. Ever Supreme Bio Technology Co's value of 72.37% is 18.8% above this industry median. Based on the distribution chart, Ever Supreme Bio Technology Co ranks #286 out of 730 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ever Supreme Bio Technology Co has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ever Supreme Bio Technology Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ever Supreme Bio Technology Co ranks #286 out of 730 companies for Gross Margin %. This puts Ever Supreme Bio Technology Co in the upper half of its industry. The industry median Gross Margin % is 60.91. Ever Supreme Bio Technology Co's value of 72.37% is 18.8% above this benchmark. While the company's 10-year median is 63.92 vs. the industry median of 60.91, Ever Supreme Bio Technology Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 730 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ever Supreme Bio Technology Co's current Gross Margin % of 72.37% is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Ever Supreme Bio Technology Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ever Supreme Bio Technology Co's current Gross Margin % is 72.37%, which is 13% above median its own 10-year median of 63.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ever Supreme Bio Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co (ROCO:6712) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$212.05, compared to a current price of NT$161.50 — trading 23.8% below its estimated fair value. The current Gross Margin % is 72.37%, which is 13% above median its 10-year median of 63.92 and 18.8% above the Biotechnology industry median of 60.91. Ever Supreme Bio Technology Co's overall GF Score™ is 88/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Ever Supreme Bio Technology Co (ROCO:6712), the current Gross Margin % is 72.37% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ever Supreme Bio Technology Co (ROCO:6712) Overvalued in 2026?
Based on GuruFocus' analysis, Ever Supreme Bio Technology Co stock appears to be undervalued.
The current stock price of NT$161.50 is trading 23.8% below its estimated GF Value™ of NT$212.05.
GuruFocus considers Ever Supreme Bio Technology Co to be Modestly Undervalued.
Key valuation signals for ROCO:6712:
Gross Margin %: 72.37% (13% above median its 10-year median of 63.92)
GF Value™: NT$212.05 vs. price of NT$161.50 (23.8% below fair value)
Industry Position: 18.8% above the Biotechnology median (#286 of 730)
No single metric tells the full story. See the ROCO:6712 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ever Supreme Bio Technology Co Business Description
Ever Supreme Bio Technology Co Ltd is a Taiwan-based company. The company is engaged in research, development, and manufacturing of new drugs related to human mesenchymal stem cells and immune cells. The company operates in two segments: Cell Preparation Business Unit and Other Operating Business. The company gained a majority of revenue from the Cell Preparation Business, which is engaged in the research, development, manufacture, and sales of various new drugs and cell preparations, and investments related to biotechnology and medical industry businesses.
88GF Score
Get the complete analysis for ROCO:6712
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6712 has been successfully added to your 
